Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to better understand the mechanism of action (MoA) of cladribine
tablets by exploring the effect on central nervous system (CNS) and blood biomarkers relevant
in the relapsing forms of multiple sclerosis (RMS; to include relapsing-remitting MS [RRMS]
or active secondary progressive MS).